white → red2
Allylescaline
4-Allyloxy-3,5-dimethoxyphenethylamine
AL, Allylmescaline
Allylescaline is a psychedelic substance in the phenethylamine and scaline classes, and is structurally related to mescaline and escaline. Otakar Leminger reported the compound in 1972,1 and Alexander Shulgin later discussed it in his 1991 book PiHKAL.2 It appeared as a novel designer drug in 2013.3 Allylescaline remains relatively uncommon, with little documented history of human use.
Dosage & Duration
Dosage
Threshold~15 mg
Light20-30 mg
Moderate30-40 mg
Strong40-60 mg
Heavy60+ mg
Duration
Onset45-240 minutes
Peak60-75 minutes
After Effects1-16 hours
Total8-12 hours
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Auditory
Pharmacology
Pharmacodynamics
In a 2025 in-vitro receptor screen, Allylescaline (allylmescaline) showed measurable binding at 5-HT1E, 5-HT2A, 5-HT2B and 5-HT2C. Binding was strongest at 5-HT2B among these measured targets. These affinity measurements do not by themselves establish partial- or full-agonist efficacy, human receptor occupancy, clinical potency or safety. [S1][S2]
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of allylescaline and the metabolism of allylescaline is unknown.
Metabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Full Tolerance
Develops almost immediately after ingestion.
Baseline Reset
7 days
Half Tolerance
Approximately 3 days
Cross Tolerance
Psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely LowAllylescaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Physical
Extremely LowNo evidence of physical dependence. The substance is described as not habit-forming.
History & Culture
Allylescaline was first documented in the scientific literature by Czech chemist Otakar Leminger in 1972.1 The compound received broader attention when American chemist Alexander Shulgin synthesized and characterized its psychoactive effects, publishing his findings…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
By Country
United StatesUnscheduled
Not directly scheduled under the Controlled Substances Act. However, due to structural similarities with mescaline, sale for human consumption or use for illicit purposes could potentially be prosecuted under the Federal Analogue Act.
JapanControlled substance
Designated as a controlled substance effective March 25, 2015.
SwitzerlandControlled (Verzeichnis E)
Specifically named and controlled under Verzeichnis E of Swiss narcotics legislation.
GermanyAnlage I BtMG
Controlled under the Narcotics Act (Betäubungsmittelgesetz) Schedule I since February 1, 1997, listed as '4-Allyloxy-3,5-dimethoxy-phenethylazan'. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensation without a license are prohibited.
United KingdomIllegal (Psychoactive Substances Act)
Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016.5
References
Source Pages
Citations
- Otakar Leminger. (1972). Příspěvek k chemii v jádře alkoxylovaných β-fenoetylaminů – II: O některých v jádře alkoxylovaných β-fenoetylaminech, resp. jejich sulfátech. Chemický Průmysl, 22, 553–557. https://isomerdesign.com/bitnest/external/ChemickyPrumysl/22.55312
- Alexander Shulgin, & Ann Shulgin. (1991). PiHKAL: A Chemical Love Story. Transform Press. https://www.erowid.org/library/books_online/pihkal/pihkal002.shtml123
- European Monitoring Centre for Drugs and Drug Addiction, & Europol. (2014). EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA. European Monitoring Centre for Drugs and Drug Addiction. https://www.euda.europa.eu/system/files/publications/814/TDAN14001ENN_475519.pdf1
- 14 nya ämnen narkotikaklassas. Läkemedelsvärlden (n.d.). https://www.lakemedelsvarlden.se/14-nya-amnen-narkotikaklassas/1
- The Psychoactive Substances Act 2016 (Commencement) Regulations 2016 (SI 2016/553). UK Government (n.d.). https://www.legislation.gov.uk/uksi/2016/553/made1
Further Reading
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Allylescaline article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
